Preliminary study of two antiviral agents for hepatitis C genotype 1.
about
Direct-acting antivirals for the treatment of chronic hepatitis C: open issues and future perspectivesTreatment for hepatitis C virus-associated cryoglobulinaemic vasculitisHepatitis C virus protease inhibitor-resistance mutations: our experience and reviewRecent Advances in Antiviral Therapy for Chronic Hepatitis CRecent advances in managing chronic HCV infection: focus on therapy in patients with severe liver diseaseKASL clinical practice guidelines: management of hepatitis CThe New Era of Interferon-Free Treatment of Chronic Hepatitis CHCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral TherapyChronic hepatitis C: future treatmentMaximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virusOral antiviral therapies for chronic hepatitis C infectionIs sustained virological response a marker of treatment efficacy in patients with chronic hepatitis C viral infection with no response or relapse to previous antiviral intervention?Antiviral treatment of hepatitis C virus infection and factors affecting efficacyEmerging therapies for the treatment of hepatitis CMiR-122 in hepatitis B virus and hepatitis C virus dual infectionDaclatasvir: potential role in hepatitis CDirect acting antivirals for the treatment of chronic viral hepatitisHepatitis C and HIV co-infection: new drugs in practice and in the pipelineBurden of pediatric hepatitis CTherapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver CirrhosisDaclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-AnalysisInterferon-free combination therapies for the treatment of hepatitis C: current insightsEvaluation of persistence of resistant variants with ultra-deep pyrosequencing in chronic hepatitis C patients treated with telaprevirHigh-throughput screening and rapid inhibitor triage using an infectious chimeric Hepatitis C virusChimeric mouse model for the infection of hepatitis B and C virusesDeep sequencing analysis of HCV NS3 resistance-associated variants and mutation linkage in liver transplant recipientsA quantitative high-resolution genetic profile rapidly identifies sequence determinants of hepatitis C viral fitness and drug sensitivityHepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agentsRational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus InfectionHepatitis C virus infection.NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection.Changes of shear-wave velocity by interferon-based therapy in chronic hepatitis C.Advances in the treatment of hepatitis C virus infectionPharmacokinetics of new oral hepatitis C antiviral drugs.Estimating the prevalence of hepatitis C infection in New York City using surveillance dataModelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration.Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome dataInvestigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development.Frontiers in the treatment of hepatitis C virus infection.Hepatitis C virus screening in patients with cancer receiving chemotherapy.
P2860
Q21265028-C16FA6D4-5723-4811-AF93-CB34CA037F26Q24188154-9F0EF4E1-596A-492A-BD6F-158802BE62D5Q24628717-7CB98FD1-53B3-410C-8D2D-D555BF369863Q26750476-1153EFBC-625F-4D5A-B14F-BB23FC7CFC42Q26752433-565CEB28-E86A-4610-A221-23F3243CD9C7Q26752471-9298925F-7A10-4B0A-96F1-B0D3AD53CAE3Q26777716-561402D3-EEDD-4782-B137-268AE5449024Q26782405-40257B23-2E1F-44C4-8D71-5FA758D9609DQ26824075-078865D3-7C8A-4E2A-B8C7-C70F5B0EA300Q26830190-1BFA2145-C35D-4517-B89C-24BEDCECF19CQ26830426-0B25662F-0922-408C-9F23-FD5EBFA121D5Q26830804-609E5E60-24D1-42B4-A2AB-F93F35711935Q26851810-EC18879A-662D-4904-BFEC-3C9D896C8C98Q27003319-0C31AA45-BBD9-44E1-87AD-28C2ECC9AF1AQ27008894-2F637954-4137-466B-8FEE-42C560BFE2FCQ27012741-4BFDE275-D632-463A-993B-1129EACCA5DEQ27022216-B9035033-4C6E-4C24-993F-E0E4D1C8FDCCQ27022596-AC49F2DD-1755-4164-91C0-B055F1E34E09Q27025476-A8D38860-8437-4BB1-ABD0-AF93413FCCC8Q28070260-8686A0A8-9341-4158-A7CF-382718A100CBQ28077287-1F52CEA2-9431-4580-B30C-908F08176DADQ28087400-46F4949C-FA9B-4423-83EE-D278F4CDF5E7Q28481622-D96E8B30-FB87-40EB-9440-058B730C07DFQ28482091-4DCE850E-37B8-4F40-A35A-BC0A86B656B7Q28534370-86F6BFF4-6D4E-4057-8503-0E719A169D71Q28534965-0530302D-7F0E-4EFD-864E-3CA7742E78E4Q28537708-83006172-E1AA-49CF-B989-56C0AFCA9AFDQ28538891-044AB617-016A-4260-BC13-7064814D79DEQ28545971-853CCFCA-98B9-4859-ACCF-4B793E6B594AQ30235491-B7C7466F-6D6B-4D39-95AB-1F5C2CA166A8Q30352718-4FAAA9E6-BA4E-4A69-8AD4-0D5467E5DE2AQ30402571-58B30633-C5BB-4120-926F-315DDF482FC1Q30415138-CE19A0D1-BD17-4888-AA63-1D5E7D984F93Q30422746-F15760E4-56AB-4566-8C59-BBDD5CCDA7B6Q30622845-EE0902AF-058C-4066-95C5-F76900CA8A3CQ30685690-2A33060D-D44A-41C5-B73C-880D60F5A841Q31042796-557FFF0F-B6F9-49EA-B176-B781CE90D871Q31051529-98B87529-B52F-40A1-A609-960D21495CD4Q33571517-79440602-616B-4845-8A7F-1FEE74485CE3Q33600085-5993535F-E5FB-455D-B3E7-FE905F1D635F
P2860
Preliminary study of two antiviral agents for hepatitis C genotype 1.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Preliminary study of two antiviral agents for hepatitis C genotype 1.
@ast
Preliminary study of two antiviral agents for hepatitis C genotype 1.
@en
Preliminary study of two antiviral agents for hepatitis C genotype 1.
@nl
type
label
Preliminary study of two antiviral agents for hepatitis C genotype 1.
@ast
Preliminary study of two antiviral agents for hepatitis C genotype 1.
@en
Preliminary study of two antiviral agents for hepatitis C genotype 1.
@nl
prefLabel
Preliminary study of two antiviral agents for hepatitis C genotype 1.
@ast
Preliminary study of two antiviral agents for hepatitis C genotype 1.
@en
Preliminary study of two antiviral agents for hepatitis C genotype 1.
@nl
P2093
P356
P1476
Preliminary study of two antiviral agents for hepatitis C genotype 1.
@en
P2093
Anna Persson
Anna S Lok
Claudia Martorell
Claudio Pasquinelli
David F Gardiner
Dennis M Grasela
Dessislava I Dimitrova
Eric Lawitz
Fiona McPhee
Gregory T Everson
P304
P356
10.1056/NEJMOA1104430
P407
P577
2012-01-01T00:00:00Z